U.S. stock prices could continue to correct, but it's too soon to say whether this is the big one.» Read More
Covidien President & CEO Jose Almeida discusses why now is the best time to separate the pharma business. "Covidien has been growing above market," he says.
Jim Cramer believes this company is about to create immense value with the stroke of a pen.
Cramer’s convinced the best way to for this health care company to maximize shareholder value is to break up.
The S&P 500 regained the 1,500 level for the first time in more than five years, but that's a milestone that could also trigger a pause, analysts say.
Wall Street's bull could take another run at the psychologically important 1,500 level as early as Friday, but that's a level that could also trigger a pause, analysts say.
A flood of earnings reports, including major technology and industrial companies, could make or break the stock market’s surprise January rally in the week ahead.
CNBC Contributor Barbara Ryan is taking the pulse of health care stocks at this year's "Woodstock" of health care.
Here are Wednesday's morning movers.
NEW YORK-- Goldman Sachs downgraded Johnson& Johnson, saying Tuesday that the current share price has captured all the potential for improved growth. However, Goldman analyst Jami Rubin wrote that Johnson& Johnson comes up short in the two areas she sees as likely to boost stock prices, new prescription drugs and capital allocation.
*Announces FDA 510 clearance and ce mark for Nellcor (TM) bedside. *Says new system will be available in the United States and throughout the eea. in the next few months.
NEW YORK-- Drug and medical device maker Covidien PLC said Tuesday it completed its $100 million purchase of CNS Therapeutics. Covidien announced it was buying CNS on Sept. 24. CNS is now part of Covidien's Mallinckrodt pharmaceuticals business.
Joe Almeida, Covidien plc chairman, president & CEO, discusses his company's medical device products and recent earnings, and the Supreme Court's health-care ruling.
Jim Cramer’s researcher, Nicole Urken, takes a look at some pockets of value creation in this unpredictable market.
Joe Almeida, Covidien president & CEO, discussed his company's strategies for growth and much more.
Few stock sectors are as reliable as drugs and health care, and astute investors know that companies such as Merck, Pfizer, and Abbott Laboratories have delivered healthy returns over the years. One stock that investors have become less enamored with, however, is Johnson & Johnson.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Every quarter hedge funds and large investors file their holdings with the SEC, revealing value picks, cyclical bets, growth opportunities and activist pushes. TheStreet.com details five stocks that hedge funds flocked to.
Barry Rosenstein, founder of Jana Partners, is best known as an activist investor. The hedge fund manager made intriguing moves in the fourth quarter, buying more shares of Apple and making an outsized bet on Marathon Petroleum.
Cramer makes the call on viewers' favorite stocks.
Happy Friday! Take a look at some of this morning's early movers: